Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting

China aims to lead next bio revolution in advanced biologics, says GlobalData

China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.

ELIX Polymers and Ayudame3D to produce prostheses using recovered ABS

Ayúdame3D has become a leading social entity in social technology.